This 2-year clinical study provides the most comprehensive assessment to date of the long-term safety of lisdexamfetamine dimesylate (LDX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

The observed effects of LDX on treatment-emergent adverse events, vital signs, and growth were consistent with findings from previous short-term randomized controlled trials of LDX; no new safety signals were reported.

LDX treatment was associated with improvements in ADHD symptoms that were maintained for the 2-year duration of the study.